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 INTRODUCTION 
 
 
The history of Celiac disease (CD) is intimately connected to the introduction of the 
cultivation of cereals for food purposes, dated to about 10,000 years ago, when it 
was introduced in the near Middle East, known for its climatic characteristics and 
those of the soil as the “Fertile Crescent” (Figure 1). However, the use of wheat, 
which constituted a fundamental moment in the switch of the population from 
nomadic to geographically stable, showed up the fact that a certain number of 
people could not tolerate this food, predominantly having intestinal problems. 
 
 
                                                         Figure 1: The Fertile Crescent 
 
However, it was only in the first century AD that this morbid condition was 
recognized as a real illness with the name “celiac diathesis”, from the Greek term 
koiliakos (of the bowel) to point out the specific place of the lesion responsible for 
the clinical pattern. In this connection, Arethaeus of Cappadocia (Fig. 2), a physician 
who lived in Rome at the time of Vespasian, hypothesized that it was a consequence 
of some intestinal alteration. 
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Figure 2 Arethaeus of Cappadocia 
 
 
Interest in this disease was rekindled towards the end of the 19
th
century, in 
1888,when an English paediatrician, Samuel Jones Gee, gave an excellent 
description of the illness in children, hypothesizing the fundamental role of feeding 
for the child’s development and control. From then onvarious hypotheses were 
formulated to explain the nature and the causes of celiac disease but it was only in 
1945 that the role of wheat flour was highlighted. Once again it was a paediatrician, 
Willem-Karel Dicke [1], that drew attention to that fact that suspension of the 
introduction of food stuffs based on wheat flour involved a dramatic improvement 
of the picture. This physician observed that his young patients clearly improved 
during the war period when they were forced to feed on a potato-based diet, while 
they again worsened when, at the end of the war, thanks to improved economic 
conditions, they went back to feedingon bread and other food stuffs containing 
gluten. 
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Since that time there has been a series of observations and discoveries [1,2,3] that 
have made it possible to clarify many of the aetiological-pathological aspects of this 
illness,which affects a rather large number of people. Epidemiological studies, which 
have gradually spread from the western world to the eastern world and to 
developing countries, have highlighted the fact that celiac disease is not an exclusive 
prerogative, as was mistakenly believed in the past, of the peoples of Europe and 
the countries of the Mediterranean area. It is found in all countries, especially those 
where immigration of populations of European origin has occurred. In Europe, 
where the consumption of wheat has constituted the basic food, the prevalence is 
estimated to be equal to 1/100 and in some studies even proves to be higher. 
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Prevalence of Celiac disease in  the world 
 
The epidemiological situation of Celiac disease drastically changed in the last 
decades of the previous century following the diffusion of very sensitive and specific 
serological tests, particularly endomysial antibody (EMA) and anti-tissue 
transglutaminase (anti-tTG)dosing. 
In the scientific world interest in this disease has therefore also been accentuated by 
the complexity of the clinical pattern, whose pathogenesis is not entirely clear. 
Table 1 shows some of the data that characterize the epidemiology of CD. 
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Prevalence in western countries: 1% 
85,000 celiacs currently in Italy 
5000 new diagnoses/year 
Ratio of 1 to 7 between diagnosed and expected cases 
Extreme variability of presentation 
More and more frequent diagnosis in adults 
Primarily extra-intestinal manifestations 
Silent-asymptomatic forms 7-8 times more frequent than 
symptomatic ones 
 
 
 
Table 1: Figures for Celiac disease (E.Ubaldi, Celiac disease in General Medicine) 
 
Lastly, females are more affected than males, with a male-to-female ratio of 1:2.8 
[4]. 
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 CELIAC DISEASE PATHOGENESIS 
 
 
Celiac disease presents a complex multifactor pathogenesis, with a strong genetic 
component, to which there are added environmental and immunological factors;it 
can be defined an autoimmune pathology, which arises in genetically predisposed 
subjects. 
 
Genetic factor: in the vast majority of patients (around 95%), there is present the 
biggest histocompatibility complex of class II HLA-DQ2 or HLA-DH8, which has 
marked affinity for peptides rich in glutamic acid that derive from deamination of 
gliadin. It is also to be noticed that in the last few years, using molecular genetics 
methods, various genetic loci have been highlighted that would appear to 
predispose the celiac subject to the disease, and precisely CELIAC1, on chromosome 
6, CELIAC2, on chromosome 5, CELIAC3, on chromosome 2, and CELIAC4,on 
chromosome 19. It therefore appears evident that the genetic factor is fundamental 
but not sufficient, as in the case of diseases with Mendelian transmission. 
 
Environmental factor: it is represented by the exposure of the intestinal mucosa to 
gluten, a protein component of cereals constituted by the peptides gliadin and 
glutenin, present in wheat as well as in a variety of cereals, like barley and rye. 
Incomplete digestion of the proteins of gluten leads to the formation of gliadin, 
which, with mechanisms that are still not well defined, overcomes the barrier 
constituted by the layer of cells of the intestinal mucosa and has the function and 
task of separating the immuno-competent cells present in the submucosa from the 
large quantity of antigens that continually reach the intestinal lumen. The peptides 
of gliadin, particularly resistant to the digestive action of pancreatic enzymes and  
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intestinal peptidase, are exposed to deamination by the transglutaminase 2 (TG2) 
enzyme, becoming extremely adhesive to the APC cells responsible for antigenic 
presentation, and they are presented, linked to the molecules HLA-DQ2 or HLA-DQ8, 
by the dendritic cells of the T lymphocytes and by these to the B lymphocytes. This 
activates an immune reaction with the formation of anti-gliadinantibodies but also 
anti-transglutaminase and anti-endomysium ones. (Fig. 3) 
 
 
 
 
Figure 3: Pathogenetic mechanism of Celiac disease 
 
There is thus an exaggerated response of cytokines and particularly of IFN-γ and 
Interleukin-15, the latter being responsible for migration and activation of IEL 
intrahepatic lymphocytes. These are responsible for the alterations that lead to 
apoptosis of enteric cells and remodelling of intestinal villi down to their 
disappearance. This harmful action is furthered by interferon-gamma activating the 
fibroblasts producing metalloproteinasis, which alter the ectocytic matrix, with 
further reduction of the mucosal barrier. (5) 
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In consequence of all this, there is atrophy of the villi
an increase in the number of intra
the duodenum and the proximal jejunum and 
ileum. This involves a reduction 
present in the intestinal lumen, 
serious as the lesions along the 
 
 
In 1992, on the basis of the histological alterations 
mucosa, Marsh [6] proposed a classification in 4 sta
 
 
                                                 Chart 
 
Stage 1: presence of slight 
papillary derma. The crypts and the villi are normal
infiltrated by small lymphocyte
, hypertrophy 
hepatic lymphocytes. These lesions initially strike 
then spread distal
in the useful surface for absorption of the 
with consequent malabsorption, which 
small intestine are extensive. 
MARSH’S  CLASSIFICATION 
 
detectable 
ges (Chart 1): 
1: Marsh’s classification 
alterations in the mucosas and deposits of IgA in the
, with the epithelium of the villi 
s. (Figure 4) 
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of the crypts and 
ly towards the 
nutrients 
will be as 
in the intestinal 
 
 
  
Figure 4: Celiac disease in stage 1: villi normal or showing slight atrophy and increase 
in the number of the intrahepatic lymphocytes. 
 
Stage 2: the villi are still normal but the crypts contain small hyperplasic 
lymphocytes. (Figure 5) 
 
 
 
Figure 5: Celiac disease in stage 2, villi with moderate atrophy, increase in the 
number of intrahepatic lymphocytes, hyperplasic appearance of glandular elements. 
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Stage 3: the villi are atrophic with hypertrophic crypts containing large and mitotic 
lymphocytes (blasts). 
Subsequently Oberhuber subdivided this stadium into: 
3a) Slight :  the villi have slightly inferior to normal height 
3 b) Moderate :  the villi are only sketched 
3 c) Severe :  one can only identify the glandular hosts 
 
Stage 4 : the architecture of the intestine is completely lost. (Figure 6) 
 
 
 
Figure 6: Celiac disease in stage 4 : total atrophy, increase in intrahepatic 
lymphocytes and hyperplasic glands 
 
More recently, in 2005, Corazza and Villanacci (7) proposed a new classification in 
which the overall appearance of the mucosa is privileged, with a distinction into 3 
degrees. 
Degree A, not atrophic, unifying stages 1 and 2 of the classification by Marsh-
Oberhuber; 
Degree B1, with partial atrophy, unifying stages 3a and 3b; 
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Degree B2, with total atrophy, corresponding to stage 3c. 
Stage 4 has been suppressed. 
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  CELIAC DISEASE CLINICAL PRESENTATION 
 
 
 
Classic Celiac disease is characterized by : 
• bloating and  abdominal pain 
• diarrhea 
• vomiting 
• weightloss 
• abundant , pale, smelly or oily stools 
dependent on the functional and anatomical damage of intestinal mucosa 
 The absorption’s changes can affect different elements and, consequently, may 
occur: 
• iron deficiency anemia 
• growth retardation 
• defatigation  caused by iron deficiency anemia and immune system activation 
• osseous  or articular dolor caused by Ca deficiency and/or  Vitamin D 
deficiency 
 
Atipical Celiac disease can be characterized by : 
• depression  or anxiety syndrome 
• prickle and numbness in the hands  and foots 
• convulsions caused by IgA anti-tissue transglutaminase 
• impotentia  and/or decreased libido caused by  testosterone  lowered 
sensibility  
15 
• infertility or miscarriages caused by Vitamin E deficiency 
• aphthous stomatitis caused  by vitamins deficiency  or due to mouth’s celiac 
disease  
• dermatitis herpetiformis caused by antibodies  antitransglutaminase subtypes 
• hemeralopia caused by Vitamina A deficiency. 
 
 In adult,  Celiac disease can manifest as :  
CLASSIC FORM : Malabsorption syndrome (diarrhea, abdominal pain, decrease of 
body weight, multiple nutritional deficiencies ) 
 
MONOSYMTOMATIC  OR  ATIPICAL  FORM :   with  non-enteric symptoms (iron 
deficiency anemia resistant to treatment  or macrocytic anemia, coagulation 
disorders  and  bleeding disorders, osseous  or articular dolor, fractures,  
osteoporosis  or rachitis, tetania, paraesthesias, aphthosus  stomatitis, dental 
hypoplasia, peripheral  neuropathy, depression syndrome, amenorrhea, 
miscarriages, infertility) 
 
SILENT FORM : asymptomatic 
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CELIAC DISEASE AND THE EYE 
 
 
 
Among observable clinical manifestations in subjects with Celiac disease little 
attention has so far been addressed to involvement of the eye, despite the reports 
present in the literature (14). Already towards the end of the last century, in 1982, 
Eliakim et coll. (15)described a case of keratocongiuntivitis in a subject with celiac 
disease and urged the medical world to pay attention to the ocular condition in 
young patients with celiac disease. 
In 2011 a wide-scale study by Mollazadegan K et coll. (16) highlighted the fact that 
the risk of onset of cataract in celiac patients is especially high in those with serious 
impairment of absorption; vitamin deficiencies and in particular lack of vitamin A 
could play a major role. The risk of cataract might also be due to increased oxidative 
and above all photo-oxidative stress consequent on alimentary disorders present in 
such patients. Chronic diarrhea can cause a malabsorption syndrome with a resulting 
from severe vitamin D deficiency.  It can cause an hypocalcemia  that contributes to 
the development of cataracts.  In fact low levels of calcium in the aqueous humor 
change the permeability of the lens epithelium, causing an imbalance in the osmotic 
equilibrium and leading to lens opacification. 
The frequency of cataracts, especially bilateral,in young subjects, according to Raina 
UK et al. (17) makes it necessity first of all to exclude the presence of celiac disease. 
Vitamin A deficiency  could lead to the appearance of a retinopathy. (18)  
This Vitamin A, in fact, is important for the function of the cones. Nyctalopia  is 
usually the first symptom in patients  and  the  fundus examination can shows from 
yellowish to white punctate lesions in the peripheral retina 
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Typically, visual function improves after one to four months of vitamin A reposition. 
Vitamin A deficiency may be associated with Pseudotumor cerebri that is 
characterized  by the presence of papilledema. The Vitamin A deficiency can lead to 
dry eye because it is necessary to maintain the proper functioning of the ocular 
epithelium surface. In these cases it is possible to see Bitot spots resulting from 
keratinization of the perilimbal conjunctiva and sometimes liquefactive necrosis of 
the cornea (keratomalacia) too. 
According to Mollazadegan K et coll. (19), the risk of uveitis would also be 
moderately increased in patients with celiac disease and, nevertheless, such as to 
involve, in cases of uveitis with unknown aetiology, the need to search for gluten 
intolerance. A gluten-freediet constitutes a fundamental element for treatment of 
this serious ocular manifestation (20.). 
In the Celiac disease  it is possible to see other ocular manifestations : orbital 
myositis,   thyroiditis associated with orbitopathy and brain occipital calcification. 
Recently, Thiago Gonçalves dos Santos et al. (21) have proposed to make a 
distinction between ocular manifestation of Celiac disease. They can be divided into 
two subgroups  : 
 
a) Manifestations related to malnutrion :  
Retinopathy: 
           Cataract; 
           Pseudotumor cerebri; 
           Dry eye 
 
b) Manifestations due to dysimmunity:  
Orbital myositis; 
            Uveitis; 
            Brain occipital calcification,. 
 
Recently, Urganci N et al. (22) have also stressed the possible co-involvement of the 
various ocular structures in celiac disease. According to these authors, young celiac 
patients in particular should undergo careful eye examinations to show up 
involvement of this organ at the right moment and to avoid serious consequences 
for sight, with further worsening of their quality of life. 
18 
  
 
 
 
 
CROHN’S DISEASE 
 
Crohn’s disease, from the name of the American pathologist that described it in 
1932, is a chronic inflammatory disease that can affect the whole alimentary tract, 
though it most frequently strikes the terminal segment of the small intestine (ileitis) 
alone or in association with the right colon (ileum-colitis) or the colon only (colitis). 
The disease affects both sexes without any preference and can arise at any age, 
though the largest number of patients, over 20%, are children and teenagers; a 
second peak appears between the ages of 50 and 70. 
Its aetiology is not yet completely defined, though numerous risk factors have been 
highlighted. The various researchers agree in believing that the disease is a 
combination of ectogenous factors (variations in diet and/orin intestinal flora 
because of both geographical changes in the patient’s life and the use of antibiotics) 
with a genetic predisposition, as the higher incidence in monozygotic twins suggests. 
The primary function of the intestinal tract, as is well known, is constituted by 
absorption of nutritive substances, with excretion of waste products, effected by the 
intestinal epithelium, which is therefore directly exposed to the external 
environment. It constitutes the most extensive surface of our body, constantly 
exposed to a variety of environmental antigens, pathogenic microbes and a vast 
community of commensals. Bacteria, in particular, constantly pass through the 
epithelial state, and consequently the whole intestine is in a constant state of low-
level inflammation; nevertheless, the regulatory mechanisms present usually limit  
19 
 this inflammation to a subclinical state. In genetically predisposed subjects, 
alteration of the barrier function of the intestinal epithelium involves loss of 
immune tolerance towards the various possible intestinal antigens, with activation 
of the dendritic cells that transport them to the intestinal lymph nodes, with 
triggering of the antibody response, and subsequent production of proinfiammatory 
cytokines and chemokines causing alterations, down to necrosis of the intestinal 
epithelium, with alteration of its specific functions. (23,24) 
From the clinical view point the picture is variable; not infrequently, for a long time 
patients only complain of altered bowel habit and above all diarrhoea, whose 
characteristics vary in relation to the place of the intestinal segment affected. In this 
connection, in ileal locations, there are raised volumes of watery faeces; in the colon 
the diarrhoea is often sanguinolent. In cases of widespread involvement of the 
alimentary tract there is constant decrease in weight associated with loss of 
appetite and, very often, fever. There is more or less constant abdominal pain 
primarily located in the lower right quadrant. 
In the most serious forms extra-intestinal manifestations are quite frequent 
(25),such as: 
Involvement of biliary ducts; 
Nodous  erythema, which can be the first manifestation associated with diarrhoea; 
Peripheral arthritis, ankylosing spondylitis, and sacroileitis, particularly evocative of 
an autoimmune process in a young patient. 
Even the eye , with a  oscillating frequency in the various studies between 6 and 
14%, is affected by the autoimmune process, although ocular complications are 
infrequent , can be associated  with significant morbidity, including blindness. In 
additions, some ocular diseases, such as uveitis and scleritis, might precede a 
diagnosis of Crohn’s disease. 
Clinical manifestations include blurred vision, teary, burning or itchy eyes, ocular 
pain, photophobia, conjunctival or sclera hyperaemia, loss of visual acuity and 
possible blindness. 
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The most common ocular findings were conjunctivitis and blepharitis followed by 
uveitis, cataract and episcleritis.  
The anterior uveitis (26) requires special compliance and adherence therapy also 
because it can be often misunderstood. 
Because the ocular complaints of IBD patients are often non-specific, it may be 
helpful to perfomed eye examinations as  a routine component in the follow-up of 
these patients. It is well-known that early diagnosis and treatment of ocular 
involvement may prevent serious ocular complications that could be associated with 
significant visual morbidity. 
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AIM  
 
Impairment of growth, a fairly common complication in patients with celiac disease 
and sometimes the only clinical manifestation, has a multifactor pathogenetic 
mechanism [27]. In this connection, according to some authors [28,29], to the 
chronic malnutrition, consequent on the serious histological damage to the 
intestinal mucosa that leads to malabsorption of essential nutrient substances, 
there is added the action of proinfiammatory cytokines like TNF-a and IL-6, which 
favour epithelial damage and directly interfere with bone growth. However, there 
are more and more numerous observations that in these patients, and in particular 
in those in whom a gluten-free diet does not lead to a return to normal bone 
growth, some alteration of the GH/IGF-1 system is present that, if not corrected, will 
make all therapeutic action vain. 
Despite the various studies in the literature [30.31.32.33], there is no uniform 
opinion on the specific role of GH. Indeed, while for some there is a deficit of the 
latter, for others, instead, the failure to respond to hormonal action is to be 
ascribed, as in the case of reduced sensitivity to testosterone, to increased bone 
receptor resistance to GH [33]. 
As is well known, among the targets of GH we also have to consider the corneal cells 
[34,35,36]. In this connection, in patients with primitive hypopituitarism, reduced 
thickness of the corneal layer has been shown, which can be corrected by GH 
replacement therapy. 
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To contribute to clarifying the role played by GH in the pathogenesis of the low 
height of patients with CD, we therefore considered it appropriate to study in a 
group of celiac patients with reduced height the degree of corneal thickness and 
intraocular pressure (IOP). We also decided to compare the data observed with 
those obtained in subjects with Crohn’s disease, since studies by Tietjen K and 
others [37] have shown that the somatic hypoevolutism detectable in subjects with 
this intestinal pathology cannot be related to impairment of the Gh - IGF-1 axis. 
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MATERIAL AND METHODS 
 
After informed consent by their parents, 30 subjects were considered,aged between 
4 and 16 years, 24 females and 6 males, presenting at the DIPROSAMI Operational 
Unit of the Paediatric Clinic of the University of Palermo. 
The inclusion of patients up to 16 was motivated by the consideration that puberty 
in patients with Celiac disease may be delayed and by the decision to appraise, as 
suggested by other authors, the possible impact of puberal sexual hormones on IGF-
1. 
20 subjects had Celiac disease and 10 Crohn’s disease. 
The diagnosis of Celiac disease was confirmed through dosing of anti-gliadin, anti-
endomysium and anti-transglutaminase antibodies and endoscopic examination 
with staging according to Marsh. 
According to the standards of reference of our laboratory, antibody dosing above 10 
U/ml was considered positive. 
The diagnosis of Crohn’s disease was confirmed through endoscopic examination 
and entero-MRI and specific serology. 
Patients submitted to growth hormone (GH) therapy or having a history of use of 
corticosteroids were excluded, because of possible suppression of the 
somatotrophic axis with interference in accurate evaluation of IGF-1. 
All subjects, on recruitment, were also submitted to evaluation of body weight, 
height and GH and IGF-1 dosing, and to a complete ophthalmologic examination 
with determination of corneal thickness and intraocular pressure. The weight was 
measured using digital scales with an approximation of 0.1 kg; the height was 
measured with a stadiometer with an approximation of 0.1 cm. 
Normal values were considered : 
1-20 ng/ ml in the prepuberal child 
< 5 ng/ml in the male adult 
24 
<10 ng/ml in the female adult 
 The IGF-1 was determined by ELISA  (OCTEIA IGF-1 kit, IDS Inc. Fontana Hillis, AZ 
USA) and the values were expressed as mg / dL. 
Normal values were considered: 
In the female subiects: 
2-5 years:   33.5 - 171.8  ng/dL   (2-5 years) 
6-8 years :    79.8 - 244.0 
9-11 years:   87.4 - 399.3 
12-15 years : 138.4 - 509.9 
16.20 years :  267.5 - 470.8 
 
In the male subiects : 
2-5 years :   27.4 - 113.5 ng/dL 
6-8 years :     54.9 - 206.4 
9-11 years :   85.2 - 248.8 
12-15 years : 115.4 - 498.2 
16.20 years :  247.3 - 481.7 
 
 
 
 
The corneal thickness  was assessed by ultrasonic pachymetry (Pachpen Accutome 
24-5100) 
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 Fig. 7: Pachpen Accutome 24-5100 
 
 The measurements (38) were taken centrally as well as at four paracentral sites 3 
mm from the corneal center at the 3, 6, 9, and 12 o'clock positions. The following 
values were considered normal : 
538 + 40micron lower than 2 years    ( < 2 years) 
546+  41micron between 2 and 4 years    ( 2  - 4 years) 
565 +  46  micron between 5 and 9 years    (5 -9 years) 
555 + 33 micron higher than 9 years (> 9years). 
 
• Intraocular pressure (IOP) was measured using a Perkins tonometer  and  the 
values were corrected in relation to the corneal thickness.  
 
 Every patient was submitted to a full ophthalmic examination that includes the 
measurement of the visual acuity and , if there is present, of the refractive power, 
eye examination both the anterior segment (conjunctiva, cornea, pupil, anterior 
chamber, lens) and the posterior segment (vitreous, fundus , vessels and optic disc). 
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Investigation also included a review of ocular motility to rule out any squint. 
The ophthalmic examination was done with direct ophthalmoscopy, that provides 
about 15 times magnification and the image formed is virtual and erect, and/or with 
slit lamp examination, that was the most important of all the ophthalmological 
instruments. 
The visual acuity of our little patients was always checked monocularly and the 
distance vision was measured using the Snellen (or equivalent) chart. 
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STATISTICAL ANALYSIS 
 
The correlations between weight percentiles and corneal thickness and between the 
height percentiles and corneal thickness were examined through linear regression 
analysis and expressed as a r squared. Data were analyzed by Statistical Software 
Graph Padprism. P<0.05 was considered statistically significant. 
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RESULTS 
 
 
 
 
The general eye examination was  normal both for patients with Celiac disease and 
patients with chronic inflammatory illness of the bowel (Crohn’s disease). 
No ocular manifestations of inflammation was observed. Both the anterior segment 
and the fundus were normal. 
18 patients (14  with Celiac disease and 4 with chronic inflammatory illness of the 
bowel ) had refractive errors (Table 4).  The others 6 subjects with Celiac disease and 
6 subjects with Crohn’s disease didn’t have any refractive errors. 12 subjects with 
Celiac disease had hypermetropia and 2 had astigmatism.  
All subjects with Crohn’s disease had hypermetropia. 
 
 
Description Celiac disease Crohn’s disease 
Hypermetropia 12 4 
Myopia 0 0 
Astigmatism 2 0 
 
Table 2 :  Classification of refractive errors of the patients both with Celiac disease 
and with chronic inflammatory illness of the bowel. 
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 The table 3 shows data related to patients with Celiac disease. 
 Age Gender Stage Antibody 
titre. 
Weight Height GH IGF-1 CCT 
   R                   L 
IOP 
1. C.G. 13 M 2 >10 50-75 % 50-75 % 2.8ng/ml 416 ng/ml   555         556  12 
2.T.G.C. 14 F 2 >10 50 % >50 % 0.28 ng/ml 410 ng/ml   518         512       13 
3. C.C. 13 M 3 >10 50 % 75 % 3.6 ng/ml 388 ng/ml   540          544 11 
4 P.M. 14 F 2 <10 50-75 % 50-75 % 7.9 ng/ml 315 ng/ml   512          536 13 
5 C-E-M. 8 F 3 >10 75  % 75 % 5.86 ng/ml 207 ng/ml   512          508 12 
6. G.F. 5 F 2 >10 50 % 50-75 % 2.4 ng/ml 142 ng/ml   518          519 10 
7 C.G. 13 F 3 >10 50  % 75 % 6.1 ng/ml 410 ng/ml   516          518 12 
8 F.D. 13 F 3 <10 50-75 % 50-75 % 4.94 ng/ml 412 ng/ml   520          518 11 
9. C..E 14 F 2 >10 50 % >50 % 0.46ng/ml 388 ng/ml   520          518 12 
10.S. A.F 10 F 3 >10 75 % 50-65 % 0.20ng/ml 164 ng/ml   555          556 12 
11 M-C. 13 F 3 >10 75  % 75  % 7.1ng/ml 387 ng/ml   544          544 14 
12 P.L. 16 F 3 >10 3-10 % 97 % 16.7 ng/ml 248 ng/ml   553          559 13 
13 M.M. 13 F 3 >10 25 % 10 % 2.1ng/ml 175 ng/ml   500          501 12 
14. F.C.E. 4 F 3 >10 10 % 75  % 9.45 ng/ml 186 ng/ml   503          502 10 
15 P.F. 15 M 2 <10 50-75 % >5O°% 5.6 ng/ml 390 ng/ml   519         517 12 
16 F.A. 11 F. 3 >10 25 % 50-75 % 0.46 ng/ml 326 ng/ml   520          518 12 
17 S.N. 12 F 3 >10 25-50 % 25-50 % 2.9 ng/ml 157 ng/ml   500          500 14 
18 P.M. 14 F 2 <10 50-75 % 50-75 5 8.2 ng/ml 415 ng/ml   526         540 13 
19 M.G. 9 F 3 >10 25-50 % 50 % 12 ng/ml 219 ng/ml   505          507 14 
20 D.C. 6 M 3 >10 25-50 % 25-50 % 14 ng/ml 188ng/ml   500          500 12 
 
Table 3: Patients with Celiac disease 
Legend: In red lower than normal values ; in boldfaced higher than normal values 
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Subjects 5,6,14,19 and 20 are naive  patients; the others are patients submitted to a 
gluten-free diet. 
 
Graph 1 and 2 show the data relating to the height percentiles, with reference to 
the Italian percentiles, and to the weight deficit in subjects with Celiac disease, all 
being treated with a gluten-free diet, except 5 subjects diagnosed for the first time. 
1 subject presented a  height  lower than 25 %; 
2 subjects presented a height between 25 and 50 %; 
4 subjects presented a height equal to 50 %;  
6 subjects presented a height between 50  and 75 % 
5  subjects presented a height equal to 75 %: 
2 subjects presented a height higher than 75 %. 
 
 
 
 
Graph 1  : Distribution of subjects with Celiac disease on the basis of height percentiles 
On the x-axis there are height percentiles and on the y-axis there is the distribution of patients 
with Celiac disease. 
The bar graph shows the distribution of subjects with Celiac disease on the basis of height 
percentiles. The frequency distribution is approximately equal to left asymmetrical distribution.  
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The subjects that presented a height between 50 and 75 % are the much more frequent than the 
other percentiles. 
As a consequence, 3 subjects had a height percentile smaller than the height of the most of the 
children their age,4 subjects had a height percentile little bit smaller than the height of the most of 
the children their age. All the others had a height percentile that was within the normal range. 
 
 
 
In consideration of  the weight , 
2 subjects  presented a weight  lower than 25°  %; 
5 subjects between 25  and 50 %; 
4 subjects equal to  50 %; 
6 subjects between 50 and 75 %; 
3  subjects higher than 75  %  
 
 
 
 
 
 
 
Graph 2 : Distribution of subjects with Celiac disease  on the basis of weight percentiles 
On the x-axis there are weight percentiles and on the y-axis there is the distribution of patients 
with Celiac disease. 
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The bar graph shows the distribution of subjects with Celiac disease on the basis of weight 
percentiles. The frequency distribution consists of a curve with three portions : the first portion of 
graph is concave down, the second is concave up and the third is concave down again. 
In this graph there are three summits at the percentiles between 25 and 50  %;  at 50 % and at 
between 50 and 75  %, but the last (between 50 and 75 %) is more frequent than the others. 
As a consequence, 7 subjects had a weight percentile smaller than the weight of the most of the 
children their age, 4 subjects had a weight percentile little bit smaller than the weight of the most 
of the children their age. All the others had a weight percentile that was within the normal range. 
 
 
 
The study of GH (Graph 3) showed normal values in 14 patients (60%); in 2 patients 
(10%) the values were higher  than those of healthy peers and only in 4 (20%) these 
values were indicative of an internal secretory deficit. 
 
 
 
Graph 3 : Distribution of subjects with Celiac disease on the basis of GH values 
 GH >  :       higher than normal values                     
GH  <  :       lower than normal values                                
GH  =  :       values    in the normal range                     
On the x-axis there are GH values and on the y-axis there is the distribution of patients with Celiac 
disease. 
33 
0
2
4
6
8
10
12
14
16
GH > GH < GH =
N. patients
GH values
GH in patients with Celiac disease
The bar graph shows the distribution of subjects with Celiac disease on the basis of  GH values. The 
frequency distribution shows that most subjects had the values of GH in the normal range. 
  
 
The values relating to IGF-1 were also in the normal range. 
Corneal thickness (Graph 4) was within the normal range in 6 subjects; in 12 the 
values were lower than the normal minimum values. 
 
Corneal thickness was within the normal range in 6 subjects; in  9 the values were 
lower than the normal minimum values. In 5 subjects the values were within the 
normal range in an eye and lower than the normal minimum values in the other.  
In  one (case 15) of the two subjects in which a higher than normal GH value was 
found, the corneal thickness proved to be lower than the expected average values 
for the relevant age.   
IOP, after correction for the corneal thickness value, proved to be normal in all 
subjects. 
 
 
Graph 4 : Corneal thickness in eyes of patients with Celiac disease 
In blue: Eyes with normal corneal thickness 
In red: Eyes with pathological corneal thickness  
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On the x-axis there are the distribution of the eyes of the patients with Celiac disease and on the 
y-axis there is the distribution of corneal thickness values. The line graph  above shows the  
distribution of the eyes of the patients with Celiac disease on the basis of the corneal thickness 
values. There are two lines  : one in blue that represents the distribution of the eyes with normal 
corneal thickness and the second in red that represents the distribution of the eyes with 
pathological corneal thickness.  
 
 
The Graph 5 shows a moderate positive correlation between height percentiles and 
reduced corneal thickness (r = 0.4793; p< 0.0001). 
 
 
 
Graph  5 : Linear regression line between height percentiles and corneal thickness 
On the x-axis there are the distribution of the height percentiles and on the y-axis there is the 
distribution of corneal thickness values. 
This graph shows a moderate positive correlation between height percentiles and reduced corneal 
thickness. 
The Graph 6 shows a very weak positive correlation between weight percentiles and 
corneal thickness  
(r = 0.1150; p= 0,0323). 
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Graph 6 : Linear regression line between weight percentiles and corneal                              
thickness 
 On the x-axis there are the distribution of the weight percentiles  and on the y-axis there is the distribution 
of corneal thickness values. 
This graph shows a very weak positive correlation between weight percentiles and corneal 
thickness. 
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In the control subjects (Table 4) the body weight proved to be markedly deficient in 
9 subjects; only in one patient was it almost normal. 
 
 Age Gender Weight Height GH IGF-I CCT 
  R              L 
IOP 
1.M.V. . 19 F 3-5 % 75 % 3.5ng/ml 326 ng /ml 560       562 13 
2. P.G. 15 M 5 % 50 % 4.8 ng/ml 210 ng/ml 528       530 12 
3.C.D. 12 F 3-5 % 50 % 6.4 ng/ml 328 ng /ml 530      527 11 
4. B.S. 11 F 5 % 10-25 % 9.5 ng/ml 360 ng/ml 520      522 12 
5.G.A. 18 F 3-5 % 50-75 % 8.6 ng/ml 310 ng/mL 534      536 13 
6. G.S. 17 M 95 % 95  % 4.4 ng/ml 282 ng/ml 528       527 13 
7.F.M. 17 F 3-5 % 50-75 % 6.2 ng/ml 278 ng/ml 532       534 12 
8.C.D. 9 F 10 % 25-50 % 1.99ng/ml 388ng/ml 510       508 10 
9.M.A. 13 F. 3-5 % 50 % 7.8ng/ml 260 ng/ml 526       524 12 
10. A.D. 12 F 25 % 40 % 6.77ng/ml 318 ng/ml 532        534 11 
 
 
Table 4. Patients with chronic inflammatory illness of the bowel (Crohn’s disease) 
 
Regarding height (Graph 7), 
1 subject presented a height between 10 and 25 % 
6 subjects presented a height between 25 and 50 % 
3 subjects presented a height between 50 and 75 % 
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Graph 7: Distribution of subjects  with Crohn's disease on the basis of height percentiles 
                               
On the x-axis there are height percentiles and on the y-axis there is the distribution of patients 
with Crohn’s disease. 
The bar graph shows the distribution of subjects with Crohn’s disease on the basis of height 
percentiles. The frequency distribution is approximately equal to bell-shaped curve distribution. 
The subjects that presented a height between 25 and 50 °C are most frequent than the other 
percentiles. 
As a consequence, 7 subjects had a height percentile smaller than the height of the most of the 
children their age, all the others had a height percentile that was within the normal range. 
 
 
The GH and GF-1 values proved to be within the normal limits in all subjects. 
Also within the normal range were the corneal thickness values ; only in one subject 
(Case 8) was a value below the norm detected (510 in Odx and 508 in Osx). 
In this group ,also, the IOP values were in the normal range. 
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 DISCUSSION 
 
 
 
 
Low height and weight deficit constitute two of the commonest manifestations of 
Celiac disease and in some patients hypoevolutism can be the manifestation and the 
only symptom of the illness (10). 
Reduced growth in children with Celiac disease is traditionally considered a 
consequence [39] of nutritional deficits due to the profound alterations that occur in 
the intestinal mucosa and significantly alter its capacity for absorption. Indeed, the 
more marked the alterations of the intestinal mucosa, the greater is the damage to 
the digestive process and absorption of nourishing substances. In our subjects too it 
was possible to highlight the fact that in those with reduced alteration of the 
mucosa, to be set in Marsh’s stage 2, there is slighter impairment of the body 
weight. The antibody titre too, an expression of the activity of the aggressive 
autoimmune process, can be indicative of a weight deficit. In subjects with a titre 
above 10 U/ml the decrease in body weight on average was 50%, and in six subject 
sit was below 50%. 
Elimination of gluten from the diet involves if not an arrest at least a deceleration of 
the autoimmune process. It is associated with an improvement in body weight and, 
often, also with an increase in height, especially in the first year of gluten restriction. 
In some patients, nevertheless, dietary correction does not replace catch-up growth 
and, therefore, other mechanisms must intervene in determining it. 
Some studies had lower than normal GH serum values, suggesting precisely in the 
internal secretory deficit of this hormone the possible cause of the marked 
deceleration of bone growth [30,31,32].  
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The association between somatic hypoevolutism and GH alteration, according  to 
Giannatasio et al. [40], would constitute an association that cannot be considered 
casual, instead, must  recognise  the pathogenetic mechanisms in the inflammatory 
disease itself. 
In this connection, it is known that in patients with Celiac disease there is internal 
secretion of ghrelin, due to alterations of the P/D1 cells located in the mucosa of the 
gastric fundus. This hormone, the internal secretion of which is precisely the task of 
these cells, in addition to favouring the absorption of food has a stimulatory action 
on the cells of the anterior lobe of the hypophysis, favouring GH secretion[38]. 
Reduced secretion of ghrelin might therefore influence growth, both through an 
insufficient supply of nourishing substances and through reduced GH 
secretion[41,42]. 
According to Iughetti L et al. [43], reduced GH secretion might also be due to a form 
of autoimmune hypophysitis with formation of somatotrophic anti-cell auto-
antibodies. Indeed, research by these authors appears to have shown in celiac 
patients with a GH deficit a high rate of anti-hypophysitis antibodies. 
On the other hand, it is known that patients with celiac diseases are frequently 
exposed [44,45,46] to autoimmune pathologies like hypothyroidism and type 1 
diabetes mellitus; the fact is that all these three conditions share a similar HLA with 
HLA DR3-DQ2 and DR4-DQ8 genotype, and therefore the possibility of an 
autoimmune hypophysitis must possibly be taken into consideration. 
Other authors, however, not having found reduced internal secretion of GH in 
subjects with retarded or failed bone growth, have hypothesized [33] possible 
increased resistance to the hormone, having noticed, in some cases, GH values 
above the norm or normal values but with low levels of IGF-1 [47,48,49]. 
As is well known, the insulin-like growth factor-1(IGF-1) is an effector 
hormone,essential for normal growth in human beings, with an important role in 
mediating the effects of growth hormone (GH). Its internal secretion(Fig. 7) mainly 
occurs in the liver cells and it is GH-dependent; indeed, its serum concentrations are 
decreased in patients with a GH deficit and increased in those with acromegaly. 
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 Fig. 7: Regulation of IGF
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Determination of corneal thickness in the patients with CD examined by us proved 
to be at the lower limits of the norm (Graph 4) in 14 subjects out of 20 (70%), as is 
noticed in cases of reduced action of hormonal activity, and proved to be reduced in 
1 patient that had raised GH values. 
In fourteen subjects the GH serum values proved to be in the normal range and only 
in two were they above the norm. One of these two subjects had a corneal thickness 
that was markedly reduced, confirming probable receptor resistance to the 
hormone. The IGF-1 serum values were in the normal range in all subjects, 
expressing a normal response to the GH stimulus. 
Hence the data found could be particularly indicative of reduced receptor sensitivity 
of osteoblasts but also of corneal receptors to the GH-IGF-1 system, like the finding 
of markedly reduced corneal thickness in 1 of the 2 patients with raised GH values. 
This hypothesis would also be confirmed by the fact that a moderate positive 
correlation is present (Graph 5) between height percentiles and reduced corneal 
thickness (r = 0.4793) and a very weak positive correlation is present (Graph 6) 
between weight percentiles and corneal thickness (r = 0.01150). 
The height deficit therefore seems to be primarily due to the reduced receptor 
sensitivity to GH and the weight deficit to impairment of the digestive function of 
the intestinal epithelium. 
The fact that the height and weight deficit involves a different pathogenetic 
mechanism finds further confirmation in the fact that, at least in our subjects, there 
is no correlation between the two values (r = 0.087). The two deficits are 
independent of one another and consequently involve different pathogenetic 
mechanisms that in some subjects may overlap. 
Nevertheless, the finding of a raised GH value in 2 subjects (10%) confirms the 
complexity of the pathogenetic mechanism at the basis of the height deficit. This 
imposes the need for careful study of the hormonal conditions of the single patient 
before beginning substitutive hormonal treatment,which may not be ethically 
correct. 
While in the majority of the subjects reduced receptor sensitivity was ascertained, 
the pathogenetic mechanism at its basis is not yet well defined. 
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 According to Griffiths [39], as already mentioned, it would be due to the action of 
proinfiammatory cytokines, which would mediate the action of IGF-1. However,this 
hypothesis does not appear very probable, also considering the fact that subjects 
with Crohn’s disease, in whom proinfiammatory cytokines are constantly found, do 
not present, at least in our case study, corneal thickness alterations. The latter 
constantly proves to be normal, as do the GH and IGF-1 values. 
The reduced receptor sensitivity, in our opinion, could have a specific genetic 
component. 
In the last decade it has been shown that in patients with Down’s syndrome 
[50,51,52] Celiac disease is also quite frequent; and a recent study by Marild K et 
coll. [51] has shown that the risk of Celiac disease in subjects with Down’s syndrome 
is 6 times higher than in normal subjects. Furthermore, in patients with Down’s 
syndrome, reduced corneal thickness is frequently found and it can evolve down to 
formation of a keratoconus. This alteration appears to be due to genetic 
impairment, as is suggested by the studies by Vincent et al. [53]. With computerized 
corneal topography the latter authors detected an altered parameter in 39% of the 
parents of children with Down’s syndrome, an alteration that would be indicative of 
the presence of a genetic anomaly responsible for the reduced corneal thickness. In 
this connection, most researchers suggest complete penetration of the factors but 
with varying phenotypic expression. In some patients heterozygous mutations of 
gene VSX1 have been described as a basic genetic defect. This gene, located on 
chromosome 20 (20p 11-21) is implicated in the synthesis of proteins that regulate 
normal corneal trophism, and indeed mutations of it are responsible for 
polymorphous corneal dystrophy and keratoconus. 
In subjects with Celiac disease too, as in those with Down’s syndrome, genetic 
mutations are quite frequent [54,55], affecting genetic loci located on different 
chromosomes. It would therefore be useful to verify whether in subjects with height 
deficit and reduced corneal thickness this gene is affected. 
Lastly, the specificity and precocity of corneal impairment make this element a sign 
that could be fundamental in the diagnosis of reduced receptor sensitivity to GH, 
making it possible not only to start more expensive and invasive investigations for 
confirmation but also monitoring of the response to the therapy. 
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It follows that ophthalmologic examination with attached cornea measurement 
should be an integral part of the clinical study of patients with Celiac disease and of 
the response to dietary and, if appropriate, pharmacological treatment. 
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CONCLUSION 
 
From our work, whose significance is nevertheless limited by the small size of the 
sample, it is possible to draw the following conclusions: 
• In children with Celiac disease, failed or limited recovery of growth, despite 
careful dietary treatment, very probably implies reduced receptor sensitivity 
to action of the GH-IGF-1 system; 
• Study of corneal thickness constitutes a valid in vivo test to appraise receptor 
response to the action of the GH-IGF-1 system; 
• Precocity of corneal impairment could constitute an easy indicator of the 
altered receptor response to the GH-IGF-1 system. 
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